Drawing for GENMEDS

USPTO serial 99199747

GENMEDS

Reviewed by CopyMark Law Group

Status 730Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
FARRAG, SHERIF G
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 730: Status 730 means you filed the first six-month extension to delay filing a Statement of Use after a Notice of Allowance. You must file a Statement of Use or another extension before the new deadline.

Need help with GENMEDS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $349*

Plus Government fees of $150

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Candice Kwok

Candice Kwok Squire Patton Boggs (US) LLP550 California Street, Suite 1100San Francisco, CA 94104United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, single-administration gene therapy products for the treatment and long-term management of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; gene therapy products for medical purposes, namely, pharmaceutical preparations for the treatment of metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; therapeutic preparations comprising viral vectors for gene delivery; biopharmaceuticals for modifying genetic expression to treat chronic and inherited conditions, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; injectable gene therapy products for use in treating metabolic, autoimmune, cardiovascular, or neurological disorders; biologics in the nature of pharmaceutical preparations for the treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders, and for the treatment of metabolic, autoimmune, cardiovascular, and neurological disorders; biological preparations for the prevention or treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; injectable pharmaceutical preparations for treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disorders; long-duration medicines for treatment of chronic diseases, namely, metabolic, autoimmune, cardiovascular, infectious, and oncological diseases, and neurological disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 4, 2026ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Oct 27, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 26, 2026EX1GSOU EXTENSION 1 GRANTED—
Oct 26, 2026EXT1SOU EXTENSION 1 FILED—
Oct 26, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 16, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 21, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 21, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 15, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 24, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 18, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 18, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 18, 2026ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED—
Jan 16, 2026GNFNNOTIFICATION OF FINAL REFUSAL EMAILED—
Jan 16, 2026GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jan 16, 2026CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Dec 26, 2025EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Dec 26, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 26, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 26, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 26, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 26, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 26, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 30, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 30, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 30, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 9, 2025DOCKASSIGNED TO EXAMINER—
May 23, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
May 23, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 23, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance